Ovid Therapeutics, Inc. (OVID)
2.80
-0.13
(-4.44%)
USD |
NASDAQ |
Aug 28, 16:00
2.85
+0.05
(+1.79%)
After-Hours: 07:43
Ovid Therapeutics Total Assets (Quarterly) : 231.97M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 231.97M |
| March 31, 2026 | 225.63M |
| December 31, 2025 | 150.93M |
| September 30, 2025 | 63.85M |
| June 30, 2025 | 77.43M |
| March 31, 2025 | 81.65M |
| December 31, 2024 | 92.17M |
| September 30, 2024 | 102.65M |
| June 30, 2024 | 118.09M |
| March 31, 2024 | 131.61M |
| December 31, 2023 | 144.03M |
| September 30, 2023 | 125.03M |
| June 30, 2023 | 136.23M |
| March 31, 2023 | 143.37M |
| December 31, 2022 | 155.27M |
| September 30, 2022 | 165.03M |
| June 30, 2022 | 177.33M |
| March 31, 2022 | 191.10M |
| December 31, 2021 | 194.54M |
| Date | Value |
|---|---|
| September 30, 2021 | 207.09M |
| June 30, 2021 | 218.00M |
| March 31, 2021 | 237.46M |
| December 31, 2020 | 75.93M |
| September 30, 2020 | 91.60M |
| June 30, 2020 | 45.36M |
| March 31, 2020 | 61.72M |
| December 31, 2019 | 80.84M |
| September 30, 2019 | 40.69M |
| June 30, 2019 | 54.91M |
| March 31, 2019 | 66.66M |
| December 31, 2018 | 47.65M |
| September 30, 2018 | 60.39M |
| June 30, 2018 | 68.61M |
| March 31, 2018 | 78.67M |
| December 31, 2017 | 89.46M |
| September 30, 2017 | 97.57M |
| June 30, 2017 | 108.01M |
| March 31, 2017 | 47.20M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.743B |
| Alnylam Pharmaceuticals, Inc. | 5.559B |
| Anika Therapeutics, Inc. | 183.47M |
| Savara, Inc. | 192.14M |
| Vericel Corp. | 502.87M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 22.08M |
| Shareholders Equity (Quarterly) | 209.89M |
| Debt to Equity Ratio | 0.0606 |
| Current Ratio | 12.39 |
| Net Debt Paydown Yield | 0.07% |